openPR Logo
Press release

ABSSSI Market Size and Share 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Prevalence, Medication, Statistics, NICE Approval, Revenue and Companies by DelveInsight

05-23-2025 12:44 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

ABSSSI Market

ABSSSI Market

ABSSSI companies working in the market are Merck, Pfizer, Paratek Pharmaceutical, Melinta Therapeutics, Allergan, Novexel, Teva Pharma, Wockhardt, Durata Therapeutics, Cubist Pharmaceutical, Sonescence, Forest Laboratories, The Medicine Company and Others.
(Albany, USA) DelveInsight's "ABSSSI Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ABSSSI, historical and forecasted epidemiology as well as the ABSSSI market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The ABSSSI market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted ABSSSI market size from 2020 to 2034, segmented by seven major markets. The Report also covers current ABSSSI treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the ABSSSI market.

Request for a Free Sample Report @ [https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some facts of the ABSSSI Market Report are:

* According to DelveInsight, ABSSSI market size is expected to grow at a decent CAGR by 2034.
* Leading ABSSSI companies working in the market are Merck, Pfizer, Paratek Pharmaceutical, Melinta Therapeutics, Allergan, Novexel, Teva Pharma, Wockhardt, Durata Therapeutics, Cubist Pharmaceutical, Sonescence, Forest Laboratories, The Medicine Company and Others.
* Key ABSSSI Therapies expected to launch in the market are Kimyrsa, Sivextro, Nuzyra, Baxdela, Dalbavancin, Orbactiv, Levonadifloxacin/Linezolid, NXL103, and others.
* As per Delveinsight's analysis, the total 7MM Incident cases of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) were 7,259,777, out of which the highest Incident cases of this disease were seen in the United States.
* As per DelveInsight's estimate, there were 1,942,229 male patients and 1,406,442 female cases suffering from ABSSSI in the United States.
* In United States, it is estimated that more than 15 million bacterial skin and skin structure infections occur, causing considerable morbidity.
* Owing to the launch of upcoming therapies, the ABSSSI market size shall increase significantly during forecast period: 2020-2034.
* In February 2020, Paratek Pharmaceuticals, Inc., launched NUZYRA intravenous and oral antibiotic in the treatment of ABSSSI.
* In January 2018, Melinta Therapeutics, Inc., launched BAXDELA for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI).

ABSSSI Overview

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are a category of bacterial infections that involve the skin and underlying soft tissues. They typically present with signs and symptoms of infection such as redness, swelling, warmth, pain, and often drainage of pus. Common types of ABSSSI include cellulitis, erysipelas, wound infections, and major cutaneous abscesses.

ABSSSI are frequently caused by gram-positive bacteria, with Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA), being the most common pathogen. Other bacteria such as Streptococcus pyogenes can also be involved. Risk factors for ABSSSI include compromised skin integrity due to cuts, abrasions, surgical wounds, chronic skin conditions, and underlying diseases such as diabetes or immune deficiencies.

Diagnosis of ABSSSI is based on clinical examination and patient history. In some cases, cultures of wound exudate or blood tests may be performed to identify the causative organism and guide antibiotic therapy.

Treatment involves appropriate antibiotic therapy tailored to the suspected or confirmed pathogen, along with supportive care measures such as wound care and pain management. For MRSA infections, specific antibiotics like vancomycin, linezolid, or daptomycin may be required. Severe cases may necessitate hospitalization and intravenous antibiotics.

Prompt and effective treatment of ABSSSI is essential to prevent complications such as sepsis, chronic wounds, or the spread of infection. With proper medical management, most patients with ABSSSI recover fully.

Learn more about ABSSSI treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ [https://www.delveinsight.com/sample-request/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

ABSSSI Market

The ABSSSI market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted ABSSSI market trends by analyzing the impact of current ABSSSI therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the ABSSSI market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated ABSSSI market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the ABSSSI market in 7MM is expected to witness a major change in the study period 2020-2034.

ABSSSI Epidemiology

The ABSSSI epidemiology section provides insights into the historical and current ABSSSI patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the ABSSSI market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about ABSSSI Epidemiology @ [https://www.delveinsight.com/sample-request/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

ABSSSI Drugs Uptake

This section focuses on the uptake rate of the potential ABSSSI drugs recently launched in the ABSSSI market or expected to be launched in 2020-2034. The analysis covers the ABSSSI market uptake by drugs, patient uptake by therapies, and sales of each drug.

ABSSSI Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on ABSSSI market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

ABSSSI Pipeline Development Activities

The ABSSSI report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses ABSSSI key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the ABSSSI pipeline development activities @ [https://www.delveinsight.com/sample-request/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

ABSSSI Therapeutics Assessment

Major key companies are working proactively in the ABSSSI Therapeutics market to develop novel therapies which will drive the ABSSSI treatment markets in the upcoming years are Merck, Pfizer, Paratek Pharmaceutical, Melinta Therapeutics, Allergan, Novexel, Teva Pharma, Wockhardt, Durata Therapeutics, Cubist Pharmaceutical, Sonescence, Forest Laboratories, The Medicine Company and Others.

Learn more about the emerging ABSSSI therapies & key companies @ [https://www.delveinsight.com/sample-request/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

ABSSSI Report Key Insights

1. ABSSSI Patient Population

2. ABSSSI Market Size and Trends

3. Key Cross Competition in the ABSSSI Market

4. ABSSSI Market Dynamics (Key Drivers and Barriers)

5. ABSSSI Market Opportunities

6. ABSSSI Therapeutic Approaches

7. ABSSSI Pipeline Analysis

8. ABSSSI Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the ABSSSI Market

Table of Contents

1. Key Insights

2. Executive Summary

3. ABSSSI Competitive Intelligence Analysis

4. ABSSSI Market Overview at a Glance

5. ABSSSI Disease Background and Overview

6. ABSSSI Patient Journey

7. ABSSSI Epidemiology and Patient Population

8. ABSSSI Treatment Algorithm, Current Treatment, and Medical Practices

9. ABSSSI Unmet Needs

10. Key Endpoints of ABSSSI Treatment

11. ABSSSI Marketed Products

12. ABSSSI Emerging Therapies

13. ABSSSI Seven Major Market Analysis

14. Attribute Analysis

15. ABSSSI Market Outlook (7 major markets)

16. ABSSSI Access and Reimbursement Overview

17. KOL Views on the ABSSSI Market

18. ABSSSI Market Drivers

19. ABSSSI Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=absssi-market-size-and-share-2034-ema-pdma-fda-approvals-clinical-trials-prevalence-medication-statistics-nice-approval-revenue-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release ABSSSI Market Size and Share 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Prevalence, Medication, Statistics, NICE Approval, Revenue and Companies by DelveInsight here

News-ID: 4033319 • Views:

More Releases from ABNewswire

Medical Device Contract Manufacturing Market Projected to Expand at ~11% CAGR Through 2030 | DelveInsight
Medical Device Contract Manufacturing Market Projected to Expand at ~11% CAGR Th …
Medical Device Contract Manufacturing Companies are Nipro Corporation, Celestica International Lp., Plexus Corp., Benchmark Electronics Inc., Flex, Ltd., Integer Holdings Corporation, Gerresheimer AG, Sanmina Corporation, West Pharmaceutical Services, Inc., Jabil Inc., Tecomet Inc., Nortech Systems Inc., TE Connectivity, Forefront Medical Technologies, Nordson Corporation, among others (Albany, USA) DelveInsight's Medical Device Contract Manufacturing Market Insights report provides the current and forecast market analysis, individual leading medical device contract manufacturing companies' market shares,
Complement Inhibitors Pipeline Market 2034: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Manufacturers, Companies by DelveInsight
Complement Inhibitors Pipeline Market 2034: EMA, PDMA, FDA Approvals, Medication …
Complement inhibitors companies are AstraZeneca, Annexon, Inc., Dianthus Therapeutics, Alsonex Pharmaceuticals, Mallinckrodt, CANbridge Pharmaceuticals, Beijing Defengrei Biotechnology, NovelMed Therapeutics, DynamiCure Biotechnology, CSL Behring, Kriya Therapeutics, Argenx, Arrowhead Pharmaceuticals, Amyndas Pharmaceuticals, Q32 Bio, Kira Pharmaceuticals, ReAlta Life Sciences, ISU Abxis, and others. (Albany, USA) DelveInsight's Complement Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging complement inhibitors, market share of individual therapies, and current and forecasted complement inhibitors
Actinic Keratosis Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Prevalence, Medication, Therapies, NICE Approvals and Companies by DelveInsight
Actinic Keratosis Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, …
Actinic Keratosis companies are VidacPharma, DFB Soria, G&E Herbal Biotechnology, Promius Pharma, Sol-Gel Technologies, PROVECTUS BIOPHARMACEUTICALS, Coegin Pharma, Jupiter Wellness, MedC Biopharma CorporationGlaukos Corporation, Ivantis Inc., Allergan, Ellex, Alcon, BVI, Johnson and Johnson Services, Inc., Microsurgical technology, Molteno Ophthalmic Ltd. ,New World Medical , Santen Pharmaceutical, Sight Scientific, Topcon Corporation, Merck & Co., Inc., Carl Zeiss AG, among others. (Albany, USA) DelveInsight's "Actinic Keratosis Market Insights, Epidemiology, and Market Forecast-2034" report
Geographic Atrophy Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Manufacturers, Companies by DelveInsight
Geographic Atrophy Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, …
Geographic Atrophy companies are Apellis Pharmaceuticals, Iveric Bio (formerly Ophthotech Corporation), Alkeus Pharmaceuticals, Hemera Biosciences, Allegro Ophthalmics, Stealth BioTherapeutics, Regenerative Patch Technologies, Novartis, Roche, Ionis Pharmaceuticals, CellCure Neurosciences (a subsidiary of Lineage Cell Therapeutics), and others. (Albany, USA) DelveInsight's "Geographic Atrophy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Geographic Atrophy, historical and forecasted epidemiology as well as the Geographic Atrophy market trends in the United States,

All 5 Releases


More Releases for ABSSSI

North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABS …
North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market: An in-depth analysis of statistics on current and emerging trends provides clarity regarding North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market dynamics. The report includes Porter's five forces to analyze the importance of various characteristics such as understanding of suppliers and customers, risks posed by various agents, competitive strength, and promising emerging
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market 2022-2028 | P …
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market report is a exploration database spread across colorful runners with multiple tables and numbers in it. The exploration covers a precious source of perceptive information for business strategists. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Industry provides the overview with growth analysis and literal & futuristic cost, profit, demand and force data (as applicable). The exploration judges give an elegant
North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABS …
Acute bacterial skin and skin structure infections (ABSSSI) are the skin and soft tissue infections that affect the epidermis, dermis, and subcutaneous tissues. The U.S. FDA defines ABSSSI as lesions with cellulitis/erysipelas, wound infections, and major cutaneous abscesses occurring in a minimum surface area of 75 cm2. Increasing number of ambulatory patients seeking treatment for skin and skin structure infections will further propel growth of the ABSSSI market. For instance,
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market – Detailed …
Acute Bacterial Skin and Skin Structure Infections Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu, growth opportunities and application landscape of the Acute Bacterial Skin and Skin Structure Infections depending on the industry's financial and non-financial impact. The complete range of information
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Rapidly Devel …
The major market driver for growth of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market is increasing research and development activities by pharmaceutical and biopharmaceutical companies to develop new products and novel treatment. For instance, in 2017, Cempra announced promising data from the phase 3 trial of Fusidic acid for the treatment of ABSSSI. In same year, Melinta Therapeutics received US FDA for its product Baxdela, a delafloxacin based
Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Syn …
Latest Trends Report On Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market 2020 :Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor